



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-368/S-009, S-010

Lilly ICOS LLC
Attention: David Riggs, Pharm.D.
U.S. Regulatory Affairs
Lilly Research Laboratories
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Riggs:

Please refer to your supplemental new drug applications dated April 20 and June 7, 2006 received April 24 and June 9, 2006, respectively, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cialis® (tadalafil), 5mg, 10mg and 20mg.

Supplemental new drug application, S-009, submitted as a “Prior Approval” supplement provides a revised Physician Insert (PI) which includes new information from a recently completed study assessing semen characteristics after 40 weeks of daily administration of tadalafil.

Supplemental new drug application, S-010, submitted as “Changes Being Effected” provides for the addition of “migraine” to the **Postmarketing Surveillance** section of the PI.

We have completed the review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, they are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed PI.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate these submissions **"FPL for approved supplement NDA 21-368/S-009 and 010."** Approval of these submissions by FDA is not required before the labeling is used.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to Division of Reproductive and Urologic Products and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
Food and Drug Administration
5901-B Ammendale Road
Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Eufrecina DeGuia, Regulatory Health Project Manager, at (301) 796-2130.

Sincerely,

{See appended electronic signature page}

Mark Hirsch, M.D.
Acting Deputy Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Mark S. Hirsch

10/23/2006 01:33:04 PM